Shionogi & Co., Ltd.'s first-quarter results for the fiscal year ending March 2027 reached record highs across the board, with revenue of ¥163.3 billion, operating profit of ¥66.9 billion, and profit attributable to owners of the parent of ¥97.7 billion, driven in part by the transfer of the edaravone business and the consolidation of 鳥居薬品 as a subsidiary. Meanwhile, the share price has recently declined, and analysts have reported cuts to their target prices.
The share price fell ¥82 over 5 trading days, from the closing price of ¥2,909 on 4 September to ¥2,827 on 11 September. Mizuho lowered its target price on 7 September, while a major Japanese securities firm cut its target to ¥3,800 on 4 September.
Shionogi & Co., Ltd.'s first-quarter results for the fiscal year ending March 2027 showed revenue up 63.7% year on year to ¥163.3 billion, operating profit up 90.6% to ¥66.9 billion, and profit attributable to owners of the parent up 148.2% to ¥97.7 billion. All three reached record highs for a first quarter.
Factors to monitor in future results include domestic and overseas revenue growth following the transfer of the edaravone business, growth in HIV royalties, the incorporation of 鳥居薬品 and JT's pharmaceutical business, and the overseas rollout of cefiderocol. Risk factors identified include potential volatility in royalties depending on sales trends for ViiV's HIV products, changes in drug prices and policy, and uncertainty surrounding infectious-disease demand.
The body of the report notes that results have been improving over the past 12 quarters, that the equity ratio remains high and stable, and that revenue and EPS growth has continued.